

**Wright Medical Group N.V.**  
**Supplemental Net Sales Information**  
(unaudited)

**Three months ended December 31, 2017 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	4%	(9%)	(4%)	2%	3%
Upper extremities	29%	9%	16%	23%	25%
Biologics	2%	30%	34%	7%	8%
Sports med & other	7%	(3%)	4%	0%	5%
<b>Total net sales</b>	14%	4%	10%	11%	13%

**Fiscal year ended December 31, 2017 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	2%	(7%)	(7%)	0%	0%
Upper extremities	19%	8%	9%	16%	16%
Biologics	5%	17%	18%	8%	8%
Sports med & other	(3%)	2%	2%	0%	0%
<b>Total net sales</b>	9%	4%	4%	8%	8%

**Wright Medical Group N.V.**

**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Income (Loss) from Continuing Operations Per Share**

(dollars in thousands, except per share data--unaudited)

	Three months ended		Fiscal year ended	
	December 31, 2017	December 25, 2016	December 31, 2017	December 25, 2016
<b>Net income (loss) from continuing operations, as reported</b>	\$ 26,852	\$ (30,002)	\$ (64,937)	\$ (164,934)
<b>Net income (loss) from continuing operations per share, as reported</b>	0.25	(0.29)	(0.62)	(1.60)
Reconciling items:				
Inventory step-up amortization	—	6,767	—	37,689
Non-cash interest expense on convertible notes <sup>1</sup>	11,746	10,755	45,489	36,567
Non-cash loss on extinguishment of debt	—	—	—	12,343
Derivatives mark-to-market adjustments <sup>2</sup>	(634)	(1,813)	(4,797)	(28,273)
Transaction and transition costs	2,915	8,422	12,400	36,374
Incentive and indirect tax projects <sup>3</sup>	(9,774)	—	(9,774)	—
Management changes	—	—	—	1,348
CVR mark-to-market adjustments <sup>2</sup>	(1,401)	(280)	5,320	8,688
Contingent consideration fair value adjustment <sup>2</sup>	(228)	93	81	469
Legal settlement	—	—	—	1,800
Costs associated with 2021 Notes issuance	—	—	—	234
Tax law reform <sup>4</sup>	(8,255)	—	(8,255)	—
Tax benefit related to realizability of net operating losses <sup>4</sup>	(16,037)	—	(24,965)	—
IRS settlement <sup>5</sup>	—	—	—	(3,073)
Tax effect of reconciling items <sup>6</sup>	(1,728)	(2,114)	(1,798)	(7,748)
Deferred tax benefit from acquired operations	—	(5,598)	—	(5,598)
<b>Non-GAAP net income (loss) from continuing operations, as adjusted</b>	<b>\$ 3,456</b>	<b>\$ (13,770)</b>	<b>\$ (51,236)</b>	<b>\$ (74,114)</b>
Add back amortization of intangible assets	6,822	7,434	28,396	28,841
<b>Adjusted non-GAAP earnings</b>	<b>\$ 10,278</b>	<b>\$ (6,336)</b>	<b>\$ (22,840)</b>	<b>\$ (45,273)</b>
Weighted-average diluted shares outstanding	106,578	103,309	104,531	102,968
<b>Adjusted non-GAAP earnings per share</b>	<b>\$ 0.10</b>	<b>\$ (0.06)</b>	<b>\$ (0.22)</b>	<b>\$ (0.44)</b>

<sup>1</sup> Impacting interest expense, net.

<sup>2</sup> Impacting other (income) expense, net.

<sup>3</sup> Incentive and indirect tax projects include \$0.6 million of other income and \$0.2 million of interest income.

<sup>4</sup> Impacting benefit from income taxes.

<sup>5</sup> IRS settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

<sup>6</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Fiscal year ended	
	December 31, 2017	December 25, 2016	December 31, 2017	December 25, 2016
<b>Net income (loss) from continuing operations</b>	\$ 26,852	\$ (30,002)	\$ (64,937)	\$ (164,934)
Interest expense, net	19,132	16,857	74,644	58,530
Benefit for income taxes	(27,470)	(6,493)	(34,968)	(13,406)
Depreciation	14,708	14,825	56,832	55,830
Amortization	6,822	7,434	28,396	28,841
<b>Non-GAAP EBITDA</b>	<b>\$ 40,044</b>	<b>\$ 2,621</b>	<b>\$ 59,967</b>	<b>\$ (35,139)</b>
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	5,262	4,515	19,393	14,416
Other (income) expense, net	(1,305)	346	5,570	(3,148)
Inventory step-up amortization	—	6,767	—	37,689
Transaction and transition costs	2,915	8,422	12,400	36,374
Incentive and indirect tax projects	(8,965)	—	(8,965)	—
Management changes	—	—	—	1,348
Legal settlement	—	—	—	1,800
Costs associated with 2021 Notes issuance	—	—	—	234
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 37,951</b>	<b>\$ 22,671</b>	<b>\$ 88,365</b>	<b>\$ 53,574</b>
Net sales from continuing operations	217,602	193,023	744,989	690,362
<b>Non-GAAP adjusted EBITDA margin</b>	<b>17.4%</b>	<b>11.7%</b>	<b>11.9%</b>	<b>7.8%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Fiscal year ended	
	December 31, 2017	December 25, 2016	December 31, 2017	December 25, 2016
<b>Gross profit from continuing operations, as reported</b>	\$ 170,324	\$ 142,440	\$ 584,042	\$ 497,955
<b>Gross margins from continuing operations, as reported</b>	<b>78.3 %</b>	<b>73.8 %</b>	<b>78.4 %</b>	<b>72.1 %</b>
Reconciling items impacting gross profit:				
Inventory step-up amortization	—	6,767	—	37,689
Transaction and transition costs	1,100	547	3,095	4,198
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 171,424</b>	<b>\$ 149,754</b>	<b>\$ 587,137</b>	<b>\$ 539,842</b>
Net sales from continuing operations	217,602	193,023	744,989	690,362
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>78.8%</b>	<b>77.6%</b>	<b>78.8%</b>	<b>78.2%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	Three months ended		Fiscal year ended	
	December 31, 2017	December 25, 2016	December 31, 2017	December 25, 2016
<b>Net sales</b>	\$ 217,602	\$ 193,023	\$ 744,989	\$ 690,362
<b>Selling, general and administrative expense, as reported</b>	\$ 133,149	\$ 140,489	\$ 525,222	\$ 541,558
Selling, general and administrative expense as a percentages of net sales, as reported	61.2 %	72.8 %	70.5 %	78.4 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	1,746	7,948	9,014	31,860
Incentive and indirect tax projects	(8,965)	—	(8,965)	—
Management changes	—	—	—	1,348
Legal settlement	—	—	—	1,800
Costs associated with 2021 Notes issuance	—	—	—	234
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 140,368</b>	<b>\$ 132,541</b>	<b>\$ 525,173</b>	<b>\$ 506,316</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>64.5%</b>	<b>68.7%</b>	<b>70.5%</b>	<b>73.3%</b>
<b>Research &amp; development expense, as reported</b>	\$ 13,144	\$ 13,809	\$ 50,115	\$ 50,514
Research & development expense as a percentages of net sales, as reported	6.0 %	7.2 %	6.7 %	7.3 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	69	(73)	291	316
<b>Research &amp; development expense, as adjusted</b>	<b>\$ 13,075</b>	<b>\$ 13,882</b>	<b>\$ 49,824</b>	<b>\$ 50,198</b>
<b>Research &amp; development expense as a percentage of net sales, as adjusted</b>	<b>6.0%</b>	<b>7.2%</b>	<b>6.7%</b>	<b>7.3%</b>